Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study

Journal of Human Hypertension volume 32, pages 20–25 (2018)Cite this article

Subjects

Abstract

Pharmacotherapy to protect the arteries may be appropriate for individuals with high-normal blood pressure who are at risk for future cardiovascular disease (CVD). Nebivolol (NEB) in contrast to atenolol (ATE) may have a beneficial effect on endothelial function and may be more effective than ATE in preventing CVD. Sixty subjects with preHTN or borderline BP and abnormal small artery elasticity (SAE) underwent evaluation with 10 tests, including large and small artery elasticity, resting and treadmill exercise BP, carotid intimal-media thickness, retinal vascular photography, micro-albuminuria, electrocardiography, echocardiography, and plasma B-type natriuretic peptide level. Each test scored as normal (0), borderline (1), or abnormal (2), and the total disease score (DS) was calculated by adding the test scores. Subjects were randomized double-blind to placebo (PLAC, n = 22), NEB 5/10 mg/day (n = 20), or ATE 25/50 mg/day (n = 18) once daily for 9 months. After 9 months, in the group receiving NEB the mean (standard deviation) DS decreased from baseline 4.3 (2.6) to 2.8 (2.4) (P < 0.007), with ATE from 5.4 (2.5) to 3.5 (1.9) (P = 0.0006), and with PLAC from 5.2 (3.0) to 4.5 (2.6) (P = 0.18). SAE increased in the NEB group from 6.0 (2.2) to 8.4 (3.4) ml/mmHg × 100 (P = 0.0001), whereas there was no significant change in the ATE and PLAC groups. Thus, nebivolol improves small artery function more than atenolol in asymptomatic subjects with preHTN or borderline BP, despite their similar BP-lowering effect.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Blood Pressure Lowering Treatment Trialists’ Collaboration, Sundström J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D, et al. Blood pressure lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384:591–8.

    Article  Google Scholar 

  2. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, et al Blood Pressure Lowering Treatment Trialists’ Collaboration. The effects of blood pressure reduction and of different blood pressure- lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4–16.

    Article  CAS  Google Scholar 

  3. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.

    Article  Google Scholar 

  4. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–785.

    Article  Google Scholar 

  5. Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009–20.

    Article  CAS  Google Scholar 

  6. Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291–7.

    Article  CAS  Google Scholar 

  7. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–67.

    Article  Google Scholar 

  8. Cohn JN, Hoke L, Whitwam W, Sommers PA, Taylor AL, Duprez D, et al. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J. 2003;146:679–85.

    Article  Google Scholar 

  9. Duprez DA, Cohn JN. Identifying early cardiovascular disease to target candidates for treatment. J Clin Hypertens. (Greenwich) 2008;10:226–31.

    Article  Google Scholar 

  10. Duprez DA, Florea N, Zhong W, Grandits GA, Hawthorne CK, Hoke L, et al. Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations. J Am Soc Hypertens. 2011;5:401–09.

    Article  Google Scholar 

  11. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20.

    Article  CAS  Google Scholar 

  12. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. ES2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1925–38.

    Article  CAS  Google Scholar 

  13. Fongemiel J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs 2015;75:1349–71.

    Article  Google Scholar 

  14. Munzel T, Gori T. Nebivolol: the somewhat-different beta- adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491–9.

    Article  Google Scholar 

  15. Maffei A, Vecchione C, Aretini A, Poulet R, Bettarini U, Gentile MT, et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens. 2006;19:579–86.

    Article  CAS  Google Scholar 

  16. Cockcroft J, Chowienczyk P, Brett S, Chen C, Dupont A, Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067–71.

    CAS  PubMed  Google Scholar 

  17. Gilani M, Kaiser DR, Bratteli CW, Alinder C, Rajala S, Bank AJ, et al. Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension. J Am Soc Hypertens. 2007;1:45–55.

    Article  Google Scholar 

  18. Finkelstein SM, Collins VR, Cohn JN. Arterial vascular compliance response to vasodilators by Fourier and pulse contour analysis. Hypertension 1988;12:380–7.

    Article  CAS  Google Scholar 

  19. Diehl KJ, Stauffer BL, Dow CA, Bammert TD, Brunjes DL, Greiner JJ, et al. Chronic nebivolol treatment suppresses endothelin-1-mediated vasoconstrictor tone in adults with elevated blood pressure. Hypertension 2016;67:1196–204.

    Article  CAS  Google Scholar 

  20. Neuman RB, Hayek SS, Poole JC, Rahman A, Menon V, Kavtaradze N, et al. Nitric oxide contributes to vasomotor tone in hypertensive African Americans treated with nebivolol and metoprolol. J Clin Hypertens. (Greenwich) 2016;18:223–31.

    Article  CAS  Google Scholar 

  21. Mason RP, Jacob RF, Corbalan JJ, Szczesny D, Matysiak K, Malinski T. The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells. BMC Pharmacol Toxicol. 2013;14:48 https://doi.org/10.1186/2050-6511-14-48.5.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Duprez DA, Jacobs DR Jr, Lutsey PL, Bluemke DA, Brumback LC, Polak JF, et al. Association of small artery elasticity with incident cardiovascular disease in older adults: the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2011;174:528–36.

    Article  Google Scholar 

  23. Peralta CA, Adeney KL, Shlipak MG, Jacobs D Jr, Duprez D, Bluemke D, et al. Structural and functional vascular alterations and incident hypertension in normotensive adults: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2010;171:63–71.

    Article  Google Scholar 

  24. Peralta CA, Jacobs DR Jr, Katz R, Ix JH, Madero M, Duprez DA, et al. Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR>60 mL/min/1.73m2: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2012;59:41–9.

    Article  Google Scholar 

  25. Saul SM, Duprez DA, Zhong W, Grandits GA, Cohn JN. Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study. J Hum Hypertens. 2013;27:362–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The EVIDENCE study was funded by a research grant from FOREST Laboratories. The study design was developed independently from FOREST Laboratories. The EVIDENCE study has been registered in ClinicalTrials.gov as NCT01522950.

Author information

Authors and Affiliations

  1. Cardiovascular Division, University of Minnesota Medical School, 420 Delaware Street Southeast, Minneapolis, MN, 55455, USA

    Daniel A. Duprez, Natalia Florea, Sue Duval, Catherine Koukol & Jay N. Cohn

Authors
  1. Daniel A. Duprez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalia Florea
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sue Duval
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catherine Koukol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jay N. Cohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jay N. Cohn.

Ethics declarations

Conflict of interest

Daniel A. Duprez has received research grants from Pfizer, Regeneron, Astra-Zeneca and Novartis. Jay N. Cohn has received a research grant form Forest Laboratories; he is an equity partner in CVC-HD, LLC. The remaining authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duprez, D.A., Florea, N., Duval, S. et al. Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study. J Hum Hypertens 32, 20–25 (2018). https://doi.org/10.1038/s41371-017-0019-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-017-0019-9

This article is cited by

Search

Advanced search

Quick links